3-to 24-month Follow-up on COVID-19 with Pulmonary Tuberculosis Survivors after Discharge:Results from a Prospective,Multicenter Study  

作　　者：WANG Jing Ya ZONG Xing Yu WU Gui Hui QI Yuan Lin LI Hui Zhen JI Xin Yu TONG Lin ZHANG Lei YANG Ming Bo YANG Pu Ye LI Ji Ke XIAO Fu Rong ZHANG Lin Song HU Yun Hong LIU Hong De XU Shou Fang SUN Sheng WU Wei MAO Ya LI Min Qing HOU Hao Hua GONG Zhao Yuan GUO Yang JIAO Li Wen QIN Jin WANG Ding Yi WANG Fang GUAN Li LIN Gang MA Yan WANG Yan Ping SHI Nan Nan 

机构地区：[1]Community Health Service Management Center,Dongcheng District,Beijing 100700,China [2]Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China [3]Public Health Clinical Center of Chengdu,Chengdu 610066,Sichuan,China [4]Yiyuan TCM Hospital,Zibo 256199,Shandong,China [5]Institute of Information on Traditional Chinese Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China [6]Xi’an Eighth Hospital,Xi’an 710000,Shaanxi,China [7]Harbin Infectious Disease Hospital,Harbin 150000,Heilongjiang,China [8]Hospital(T.C.M)Affiliated to Southwest Medical University,Luzhou 646000,Sichuan,China [9]Xingtai Hospital of Chinese Medicine,Xingtai 054000,Hebei,China [10]Shijiazhuang Fifth Hospital,Shijiazhuang 050000,Hebei,China [11]Jiamusi Infectious Disease Hospital,Jiamusi 154000,Heilongjiang,China [12]Chengde Hospital of Traditional Chinese Medicine,Chengde 067040,Hebei,China [13]Hanzhong Central Hospital,Hanzhong 723000,Shaanxi,China [14]Ankang Hospital of Traditional Chinese Medicine,Ankang 725000,Shaanxi,China [15]Department of Traditional Chinese medicine,Dazhou Central Hospital,Dazhou 635000,Sichuan,China [16]China National Medicines Corporation Ltd,Beijing 100077,China [17]Beijing University of Chinese Medicine,Beijing 101121,China [18]Infectious Disease Hospital of Heilongjiang Province,Harbin 150030,Heilongjiang,Chin

出　　处：《Biomedical and Environmental Sciences》2022年第12期1091-1099,共9页生物医学与环境科学（英文版）

基　　金：supported by the Fundamental Research Funds for the Central public welfare research institutes[Z0734];Scientific and technological innovation project of CACMS[CI2021B003,CI2021A01314,CI2021A00704];National Natural Science Foundation of China[82274350];COVID-19 project of the National Administration of Traditional Chinese Medicine[GZY-KJS2021-007,2020ZYLCYJ05-13,2020ZYLCYJ07-5]。

摘　　要：Objective Coronavirus disease 2019(COVID-19)and tuberculosis(TB)are major public health and social issues worldwide.The long-term follow-up of COVID-19 with pulmonary TB(PTB)survivors after discharge is unclear.This study aimed to comprehensively describe clinical outcomes,including sequela and recurrence at 3,12,and 24 months after discharge,among COVID-19 with PTB survivors.Methods From January 22,2020 to May 6,2022,with a follow-up by August 26,2022,a prospective,multicenter follow-up study was conducted on COVID-19 with PTB survivors after discharge in 13 hospitals from four provinces in China.Clinical outcomes,including sequela,recurrence of COVID-19,and PTB survivors,were collected via telephone and face-to-face interviews at 3,12,and 24 months after discharge.Results Thirty-two COVID-19 with PTB survivors were included.The median age was 52(45,59)years,and 23(71.9%)were men.Among them,nearly two-thirds(62.5%)of the survivors were moderate,three(9.4%)were severe,and more than half(59.4%)had at least one comorbidity(PTB excluded).The proportion of COVID-19 survivors with at least one sequela symptom decreased from 40.6%at 3 months to 15.8%at 24 months,with anxiety having a higher proportion over a follow-up.Cough and amnesia recovered at the 12-month follow-up,while anxiety,fatigue,and trouble sleeping remained after 24months.Additionally,one(3.1%)case presented two recurrences of PTB and no re-positive COVID-19during the follow-up period.Conclusion The proportion of long symptoms in COVID-19 with PTB survivors decreased over time,while nearly one in six still experience persistent symptoms with a higher proportion of anxiety.The recurrence of PTB and the psychological support of COVID-19 with PTB after discharge require more attention.

关 键 词：COVID-19 Pulmonary tuberculosis Long-term SEQUELA RECURRENCE Re-positive 

分 类 号：R563.1[医药卫生—呼吸系统] R521[医药卫生—内科学]